<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590836</url>
  </required_header>
  <id_info>
    <org_study_id>NN5401-1979</org_study_id>
    <secondary_id>2011-003797-90</secondary_id>
    <secondary_id>U1111-1123-3837</secondary_id>
    <nct_id>NCT01590836</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the
      pharmacodynamic response (the effect of the investigated drug on the body) of insulin
      degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the glucose infusion rate curve during one dosing interval</measure>
    <time_frame>At steady state (0-24 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum glucose infusion rate (GIRmax)</measure>
    <time_frame>At steady state (within 0-24 hours after last dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin degludec concentration-time curve during one dosing interval</measure>
    <time_frame>At steady state (within 0-24 hours after last dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum insulin degludec concentration</measure>
    <time_frame>At steady state (within 0-24 hours after last dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin aspart concentration-time curve</measure>
    <time_frame>From 0 to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum insulin aspart concentration</measure>
    <time_frame>Within 0-12 hours after dosing of IDegAsp</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>IDeg--&gt;IDegAsp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).</description>
    <arm_group_label>IDeg--&gt;IDegAsp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart</intervention_name>
    <description>Single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDeg--&gt;IDegAsp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months

          -  Treated with multiple daily insulin injections or continuous subcutaneous insulin
             infusion (CSII) for at least 12 months

          -  Body mass index (BMI) 18.0-28.0 kg/m^2 (both inclusive)

          -  Glycosylated haemoglobin (HbA1c) maximum 9.5 %

          -  Fasting C-peptide maximum 0.3 nmol/L

        Exclusion Criteria:

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per day)

          -  Not able or willing to refrain from smoking, use of nicotine gum or transdermal
             nicotine patches during the inpatient period

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Surgery or trauma with significant blood loss (more than 500 mL) within the last 3
             months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Ther. 2014 Jun;5(1):255-65. doi: 10.1007/s13300-014-0070-2. Epub 2014 Jun 3.</citation>
    <PMID>24888255</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

